Joanna Yang

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Hepatology · 2009 · 816 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Antimicrobial Agents and Chemotherapy · 2006 · 239 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis

Eugene R. Schiff, Halis Şimşek, William M. Lee et al. · The American Journal of Gastroenterology · 2008 · 137 citations

Medicine, Pharmacology, Pharmacotherapy +17

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy

Daniel Shouval, Ching‐Lung Lai, Ting‐Tsung Chang et al. · Journal of Hepatology · 2008 · 105 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens

George A. Richard, Chavaramplakic P. Mathew, Judith M Kirstein et al. · Urology · 2002 · 50 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11